PL1994055T3 - Przeciwciała anty-5T4 i ich zastosowanie - Google Patents

Przeciwciała anty-5T4 i ich zastosowanie

Info

Publication number: PL1994055T3
Authority: PL; Poland
Prior art keywords: antibodies
Prior art date: 2006-03-10

Application number

PL07758256T

Other languages

English (en)

Inventor

Erwin R Boghaert

Nitin K Damle

Philip Ross Hamann

Kiran Khandke

Arthur Kunz

Kimberly A Marquette

Lioudmila Tchistiakova

Davinder Gill

Kodangattil Raman Sreekumar

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-10

Filing date

2007-03-09

Publication date

2015-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1994055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-09 Application filed by Wyeth Llc filed Critical Wyeth Llc

2015-02-27 Publication of PL1994055T3 publication Critical patent/PL1994055T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Microbiology (AREA)
Zoology (AREA)
Toxicology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL07758256T 2006-03-10 2007-03-09 Przeciwciała anty-5T4 i ich zastosowanie PL1994055T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US78134606P	2006-03-10	2006-03-10
US89124807P	2007-02-23	2007-02-23
EP07758256.7A EP1994055B1 (en)	2006-03-10	2007-03-09	Anti-5t4 antibodies and uses thereof
PCT/US2007/063685 WO2007106744A2 (en)	2006-03-10	2007-03-09	Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
PL1994055T3 true PL1994055T3 (pl)	2015-02-27

Family

ID=38445207

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07758256T PL1994055T3 (pl)	2006-03-10	2007-03-09	Przeciwciała anty-5T4 i ich zastosowanie

Country Status (29)

Country	Link
US (5)	US8044178B2 (pl)
EP (3)	EP2368914B1 (pl)
JP (1)	JP5523824B2 (pl)
KR (2)	KR101443752B1 (pl)
CN (1)	CN101437850B (pl)
AR (1)	AR059809A1 (pl)
AU (1)	AU2007226696C1 (pl)
BR (1)	BRPI0708771B8 (pl)
CA (1)	CA2645097C (pl)
CR (1)	CR10273A (pl)
DK (2)	DK2368914T3 (pl)
EC (1)	ECSP088733A (pl)
ES (2)	ES2498517T3 (pl)
GT (1)	GT200800181A (pl)
IL (2)	IL193986A (pl)
MX (1)	MX2008011492A (pl)
MY (1)	MY148763A (pl)
NO (1)	NO20083891L (pl)
NZ (2)	NZ571208A (pl)
PA (1)	PA8718601A1 (pl)
PE (1)	PE20080119A1 (pl)
PL (1)	PL1994055T3 (pl)
PT (1)	PT1994055E (pl)
SA (1)	SA07280101B1 (pl)
SG (1)	SG170091A1 (pl)
SI (1)	SI1994055T1 (pl)
TW (2)	TWI409277B (pl)
WO (1)	WO2007106744A2 (pl)
ZA (1)	ZA200808075B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008054431A2 (en) *	2005-12-23	2008-05-08	Board Of Regents Of The University Of Texas System	Anti-hyperproliferative therapies targeting hdgf
SG170091A1 (en)	2006-03-10	2011-04-29	Wyeth Corp	Anti-5t4 antibodies and uses thereof
EP2064325B1 (en)	2006-09-01	2011-12-07	Therapeutic Human Polyclonals, Inc.	Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US9340774B2 (en)	2009-03-27	2016-05-17	Wyeth Llc	Tumor-initiating cells and methods for using same
GB0918383D0 (en) *	2009-10-20	2009-12-02	Cancer Rec Tech Ltd	Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
MX2012011629A (es) *	2010-04-07	2013-03-05	Abbvie Inc	Proteinas de union a tnf-alfa.
CA2826563C (en) *	2011-02-07	2020-10-20	Paul Kussie	Methods and systems for treating eclampsia and pre-eclampsia
HUE031017T2 (en) *	2011-04-01	2017-06-28	Wyeth Llc	Antibody Drug Conjugates
US9505847B2 (en)	2011-08-22	2016-11-29	Cnj Holdings Inc	Clostridium difficile antibodies
MX2014003313A (es)	2011-09-23	2014-07-09	Amgen Res Munich Gmbh	Moleculas de union biespecificas para 5t4 y cd3.
WO2013068874A1 (en)	2011-11-11	2013-05-16	Pfizer Inc.	Antibody-drug conjugates
US10254286B2 (en)	2012-01-24	2019-04-09	Pfizer Inc.	Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
MX2015007446A (es)	2012-12-12	2015-12-07	Vasculox Inc	Anticuerpos terapeuticos para cd47.
US9221908B2 (en)	2012-12-12	2015-12-29	Vasculox, Inc.	Therapeutic CD47 antibodies
WO2014137931A1 (en) *	2013-03-06	2014-09-12	Imaginab, Inc.	Antigen binding constructs to 5t4
CA2905418C (en) *	2013-03-13	2023-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for modulating chemotherapeutic cytotoxicity
CA2915960A1 (en) *	2013-06-17	2014-12-24	Asana Biosciences, Llc	5t4-targeted immunofusion molecule and methods
CA2927022C (en)	2013-10-11	2018-08-21	Asana Biosciences, Llc	Protein-polymer-drug conjugates
WO2015054659A1 (en)	2013-10-11	2015-04-16	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
RU2016119491A (ru)	2013-11-04	2017-12-11	Пфайзер Инк.	Конъюгаты антитела к efna4 с лекарственным средством
WO2015155345A1 (en) *	2014-04-11	2015-10-15	Medimmune Limited	Antibodies and antibody-drug conjugates
DK3151865T3 (da)	2014-05-22	2021-10-25	Byondis Bv	Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
US10647768B2 (en)	2014-05-29	2020-05-12	Macrogenics, Inc.	Multi-chain polypeptide-containing tri-specific binding molecules
US10752684B2 (en)	2014-07-29	2020-08-25	Cellectis	ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en)	2014-07-31	2016-02-04	Cellectis	Ror1 specific multi-chain chimeric antigen receptor
WO2016034666A1 (en) *	2014-09-04	2016-03-10	Cellectis	Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20160251417A1 (en) *	2015-01-22	2016-09-01	Prothena Biosciences Limited	Antibodies recognizing medin
TW201706300A (zh)	2015-05-20	2017-02-16	瑟勒提斯公司	用於癌症免疫療法之抗－ｇｄ３專一性嵌合抗原受體
CN116425875A (zh)	2015-09-18	2023-07-14	安驰肿瘤公司	治疗性cd47抗体
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
KR20180083425A (ko) *	2015-11-24	2018-07-20	신톤 바이오파머슈티칼즈 비.브이.	항-5t4 항체 및 항체-약물 접합체
CN110698559B (zh) *	2015-12-24	2021-11-26	凯惠科技发展(上海)有限公司	一种tpbg抗体及其制备方法、其偶联物和应用
SG10201912556VA (en) *	2016-07-20	2020-02-27	Aerpio Therapeutics Inc	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3529276A4 (en)	2016-10-21	2020-06-17	Arch Oncology, Inc.	CD47 THERAPEUTIC ANTIBODIES
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
CN108084265B (zh) *	2016-11-23	2021-07-02	复旦大学	特异性结合人的5t4抗原的全人源单域抗体及其应用
CN108285487B (zh) *	2017-01-08	2021-02-19	浙江昭华生物医药有限公司	抗5t4抗体-药物偶联物及其应用
BR112019017628A2 (pt)	2017-02-24	2020-07-07	Macrogenics, Inc.	molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3595705A1 (en) *	2017-03-15	2020-01-22	Oxford BioMedica (UK) Limited	Method
WO2018184558A1 (zh) *	2017-04-05	2018-10-11	凯惠科技发展(上海)有限公司	一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
MY200973A (en)	2017-04-11	2024-01-26	Inhibrx Inc	Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
US20200165351A1 (en) *	2017-06-06	2020-05-28	The Regents Of The University Of California	Humanized anti-n-cadherin antibodies and uses thereof
US11725060B2 (en)	2017-07-20	2023-08-15	Aptevo Reserch and Development LLC	Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
US11638760B2 (en)	2017-11-27	2023-05-02	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh)	2017-12-21	2020-10-09	梅尔莎纳医疗公司	吡咯并苯并二氮呯抗体共轭物
CN108187065B (zh) *	2017-12-29	2023-04-28	广东众生药业股份有限公司	抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
JP7462560B2 (ja)	2018-01-03	2024-04-05	パレオンファーマシューティカルズインコーポレイテッド	組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
MA52152A (fr)	2018-03-12	2021-01-20	Genmab As	Anticorps
TW202010757A (zh)	2018-04-11	2020-03-16	美商英伊布里克斯公司	具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020023553A1 (en)	2018-07-24	2020-01-30	Inhibrx, Inc.	Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
AU2019356573B2 (en)	2018-10-11	2025-12-18	Inhibrx Biosciences, Inc.	PD-1 single domain antibodies and therapeutic compositions thereof
CA3117050A1 (en)	2018-10-29	2020-05-07	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
US12674001B2 (en)	2019-09-12	2026-07-07	Genmab A/S	Method of treating cancer by administering an antibody which binds to 5T4
EP4097129A1 (en)	2020-01-29	2022-12-07	Inhibrx, Inc.	Cd28 single domain antibodies and multivalent and multispecific constructs thereof
JP7745556B2 (ja)	2020-02-21	2025-09-29	マクロジェニクス，インコーポレーテッド	Ｃｄ１３７結合分子及びその使用
US20220251239A1 (en) *	2020-10-22	2022-08-11	Actinium Pharmaceuticals, Inc.	Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
JP2023546679A (ja) *	2020-10-22	2023-11-07	アクティニウムファーマシューティカルズインコーポレイテッド	がん治療における放射免疫療法とｃｄ４７遮断の併用
US20220288244A1 (en) *	2020-10-22	2022-09-15	Actinium Pharmaceuticals, Inc.	Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
KR20230131236A (ko) *	2021-01-06	2023-09-12	팔레온 파마슈티칼스 인크.	항-pd-l1 항체 및 이의 융합 단백질
JP2025506248A (ja) *	2022-02-21	2025-03-07	コンセプトトゥーメディシンバイオテックカンパニー，リミテッド	抗５ｔ４抗体およびその使用
TW202400639A (zh) *	2022-05-13	2024-01-01	美商艾克塞里克斯公司	5t4結合劑及其用途
JP2025537044A (ja)	2022-09-30	2025-11-13	シャンハイドーァノボファーマテックカンパニー，リミティド	ベンザゼピン誘導体、それを含む複合体およびその応用
EP4353220A1 (en) *	2022-10-12	2024-04-17	Pierre Fabre Medicament	Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
CN116715773B (zh) *	2023-02-28	2024-03-01	星奕昂(上海)生物科技有限公司	一种靶向5t4的抗体及其应用
JP2026510761A (ja) *	2023-03-08	2026-04-10	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	抗５ｔ４抗体及びその使用
AU2024238898A1 (en) *	2023-03-22	2025-10-16	Salubris Biotherapeutics, Inc.	Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
WO2024208145A1 (zh) *	2023-04-03	2024-10-10	非同（成都）生物科技有限公司	抗5t4抗体及其应用
CN121399157A (zh)	2023-06-12	2026-01-23	美国安进公司	淋巴毒素β受体激动剂结合蛋白
CN120204418A (zh)	2023-12-27	2025-06-27	上海迪诺医药科技有限公司	环状二核苷酸化合物、其偶联物及应用
TW202611088A (zh)	2024-07-23	2026-03-16	美商雅博得樂醫療公司	5t4結合多肽及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5079233A (en)	1987-01-30	1992-01-07	American Cyanamid Company	N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en)	1987-01-30	1991-08-06	American Cyanamid Company	Dihydro derivatives of LL-E33288 antibiotics
US5108912A (en)	1987-01-30	1992-04-28	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US5053394A (en)	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE68923027D1 (de) *	1988-03-04	1995-07-20	Cancer Res Campaign Tech	Antigene.
US5869053A (en)	1988-03-04	1999-02-09	Cancer Research Campaign Technology, Ltd.	5T4 antigen from human trophoblasts
KR0162259B1 (ko)	1989-12-05	1998-12-01	아미 펙터	감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
GB9116610D0 (en)	1991-08-01	1991-09-18	Danbiosyst Uk	Preparation of microparticles
US6310185B1 (en)	1994-03-08	2001-10-30	Memorial Sloan Kettering Cancer Center	Recombinant human anti-Lewis Y antibodies
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en)	1994-07-07	1997-05-06	Ortho Pharma Corp	Lyophilized imaging agent formulation
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1997026885A1 (en)	1996-01-23	1997-07-31	The General Hospital Corporation Doing Business As Massachusetts General Hospital	Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
PT1012259E (pt)	1997-06-04	2009-11-06	Oxford Biomedica Ltd	Vector dirigido a tumor
GB2378704B (en)	1998-11-18	2003-05-07	Oxford Biomedica Ltd	Uses of 5t4 antigen
GB2370571B (en)	1998-11-18	2003-05-07	Oxford Biomedica Ltd	A modified 5t4 antigen
EP2042598A1 (en)	1998-11-18	2009-04-01	Oxford Biomedica (UK) Limited	5T4 tumour-associated antigen for use in tumour immunotherapy
US6309633B1 (en)	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1130094A3 (en) *	1999-07-08	2001-11-21	Helix Research Institute	Primers for synthesizing full length cDNA clones and their use
WO2001062299A2 (en)	2000-02-28	2001-08-30	Shearwater Corporation	Water-soluble polymer conjugates of artelinic acid
IL154751A0 (en)	2000-08-03	2003-10-31		Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US7402666B2 (en) *	2000-11-13	2008-07-22	Oxford Biomedica (Uk) Ltd.	Nucleotide encoding canine 5T4 antigen
AU2002327164A1 (en)	2001-01-29	2002-12-09	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
AU2002348477A1 (en)	2001-05-01	2002-12-23	The General Hospital Corporation	Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en)	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
US6997863B2 (en)	2001-07-25	2006-02-14	Triton Biosystems, Inc.	Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en)	2001-11-02	2002-01-02	Oxford Biomedica Ltd	Antigen
GB0203419D0 (en) *	2002-02-13	2002-04-03	Oxford Biomedica Ltd	Peptide
AU2003210060B2 (en)	2002-03-22	2010-02-25	Aprogen, Inc.	Humanized antibody and process for preparing same
BR122019027966B8 (pt)	2002-05-02	2021-07-27	Wyeth Corp	conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
TW200539855A (en)	2004-03-15	2005-12-16	Wyeth Corp	Calicheamicin conjugates
CA2571743A1 (en)	2004-06-30	2006-01-12	International Bioimmune Systems, Inc.	Humanized monoclonal antibody 31.1 as an anticancer agent
CA2578131A1 (en)	2004-09-10	2006-03-23	Wyeth	Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EA200700751A1 (ru) *	2004-10-05	2008-06-30	Элан Фарма Интернэшнл Лимитед	Способы и композиции для улучшения продуцирования рекомбинантного белка
SG170091A1 (en) *	2006-03-10	2011-04-29	Wyeth Corp	Anti-5t4 antibodies and uses thereof
NO3056203T3 (pl)	2010-04-21	2018-05-12
HUE031017T2 (en)	2011-04-01	2017-06-28	Wyeth Llc	Antibody Drug Conjugates

2007
- 2007-03-09 SG SG201101720-9A patent/SG170091A1/en unknown
- 2007-03-09 MY MYPI20084016A patent/MY148763A/en unknown
- 2007-03-09 AR ARP070100988A patent/AR059809A1/es active IP Right Grant
- 2007-03-09 EP EP11154157.9A patent/EP2368914B1/en not_active Revoked
- 2007-03-09 TW TW096108184A patent/TWI409277B/zh not_active IP Right Cessation
- 2007-03-09 SI SI200731486T patent/SI1994055T1/sl unknown
- 2007-03-09 NZ NZ571208A patent/NZ571208A/en not_active IP Right Cessation
- 2007-03-09 BR BRPI0708771A patent/BRPI0708771B8/pt not_active IP Right Cessation
- 2007-03-09 DK DK11154157.9T patent/DK2368914T3/en active
- 2007-03-09 ES ES07758256.7T patent/ES2498517T3/es active Active
- 2007-03-09 PA PA20078718601A patent/PA8718601A1/es unknown
- 2007-03-09 WO PCT/US2007/063685 patent/WO2007106744A2/en not_active Ceased
- 2007-03-09 KR KR1020137000307A patent/KR101443752B1/ko not_active Expired - Fee Related
- 2007-03-09 EP EP07758256.7A patent/EP1994055B1/en not_active Revoked
- 2007-03-09 PL PL07758256T patent/PL1994055T3/pl unknown
- 2007-03-09 NZ NZ596295A patent/NZ596295A/xx not_active IP Right Cessation
- 2007-03-09 AU AU2007226696A patent/AU2007226696C1/en not_active Ceased
- 2007-03-09 DK DK07758256.7T patent/DK1994055T3/da active
- 2007-03-09 CA CA2645097A patent/CA2645097C/en not_active Expired - Fee Related
- 2007-03-09 PT PT77582567T patent/PT1994055E/pt unknown
- 2007-03-09 MX MX2008011492A patent/MX2008011492A/es active IP Right Grant
- 2007-03-09 EP EP18213944.4A patent/EP3539989A1/en not_active Withdrawn
- 2007-03-09 TW TW102115071A patent/TWI421257B/zh not_active IP Right Cessation
- 2007-03-09 KR KR1020087024914A patent/KR101264216B1/ko not_active Expired - Fee Related
- 2007-03-09 CN CN200780016577XA patent/CN101437850B/zh not_active Expired - Fee Related
- 2007-03-09 US US11/684,329 patent/US8044178B2/en not_active Expired - Fee Related
- 2007-03-09 PE PE2007000262A patent/PE20080119A1/es active IP Right Grant
- 2007-03-09 ES ES11154157T patent/ES2712942T3/es active Active
- 2007-03-09 JP JP2009500565A patent/JP5523824B2/ja not_active Expired - Fee Related
- 2007-03-10 SA SA7280101A patent/SA07280101B1/ar unknown
2008
- 2008-09-05 CR CR10273A patent/CR10273A/es not_active Application Discontinuation
- 2008-09-09 IL IL193986A patent/IL193986A/en active IP Right Grant
- 2008-09-10 GT GT200800181A patent/GT200800181A/es unknown
- 2008-09-10 EC EC2008008733A patent/ECSP088733A/es unknown
- 2008-09-11 NO NO20083891A patent/NO20083891L/no not_active Application Discontinuation
- 2008-09-19 ZA ZA2008/08075A patent/ZA200808075B/en unknown
2011
- 2011-08-11 US US13/208,162 patent/US8759495B2/en not_active Expired - Fee Related
2014
- 2014-05-29 US US14/290,345 patent/US20140308302A1/en not_active Abandoned
2015
- 2015-07-30 IL IL240245A patent/IL240245A/en active IP Right Grant
- 2015-12-16 US US14/971,536 patent/US9902771B2/en not_active Expired - Fee Related
2018
- 2018-01-30 US US15/883,759 patent/US20180162937A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2368914T3 (en)	2019-03-04
IL193986A (en)	2015-08-31
IL240245A0 (en)	2015-09-24
BRPI0708771A2 (pt)	2011-06-14
GT200800181A (es)	2010-05-25
ECSP088733A (es)	2008-10-31
US9902771B2 (en)	2018-02-27
CA2645097A1 (en)	2007-09-20
US8759495B2 (en)	2014-06-24
ZA200808075B (en)	2012-03-28
KR101264216B1 (ko)	2013-05-31
TWI421257B (zh)	2014-01-01
SG170091A1 (en)	2011-04-29
SI1994055T1 (sl)	2014-08-29
NZ596295A (en)	2013-01-25
IL193986A0 (en)	2011-08-01
AR059809A1 (es)	2008-04-30
HK1121473A1 (en)	2009-04-24
ES2498517T3 (es)	2014-09-24
US20180162937A1 (en)	2018-06-14
WO2007106744A2 (en)	2007-09-20
CN101437850A (zh)	2009-05-20
ES2712942T3 (es)	2019-05-16
BRPI0708771B1 (pt)	2019-10-22
KR20130018980A (ko)	2013-02-25
CN101437850B (zh)	2013-10-09
EP1994055B1 (en)	2014-07-02
WO2007106744A8 (en)	2008-10-02
TW200804424A (en)	2008-01-16
PE20080119A1 (es)	2008-03-04
NZ571208A (en)	2011-12-22
DK1994055T3 (da)	2014-08-25
PT1994055E (pt)	2014-09-15
AU2007226696C1 (en)	2016-02-04
US20140308302A1 (en)	2014-10-16
MX2008011492A (es)	2008-09-22
JP2009529578A (ja)	2009-08-20
US20070231333A1 (en)	2007-10-04
TWI409277B (zh)	2013-09-21
MY148763A (en)	2013-05-31
WO2007106744A3 (en)	2007-11-29
US8044178B2 (en)	2011-10-25
AU2007226696B2 (en)	2013-08-29
KR20080106345A (ko)	2008-12-04
AU2007226696A1 (en)	2007-09-20
EP2368914B1 (en)	2019-01-02
SA07280101B1 (ar)	2011-10-03
RU2008137074A (ru)	2010-04-20
BRPI0708771B8 (pt)	2021-05-25
IL240245A (en)	2017-05-29
NO20083891L (no)	2008-12-03
TW201335189A (zh)	2013-09-01
KR101443752B1 (ko)	2014-09-26
US20120064600A1 (en)	2012-03-15
US20160185859A1 (en)	2016-06-30
CA2645097C (en)	2019-09-17
EP2368914A1 (en)	2011-09-28
EP3539989A1 (en)	2019-09-18
CR10273A (es)	2008-11-26
EP1994055A2 (en)	2008-11-26
JP5523824B2 (ja)	2014-06-18
PA8718601A1 (es)	2009-05-15

Publication	Publication Date	Title
IL240245A0 (en)	2015-09-24	Antibodies against 5t4 and their uses
IL272883A (en)	2020-04-30	Monoclonal antibodies and their uses
IL195658A0 (en)	2011-08-01	Anti-nkg2a antibodies and uses thereof
IL196397A0 (en)	2011-08-01	Prlr-specific antibody and uses thereof
PL2099826T3 (pl)	2014-04-30	Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
IL205355A0 (en)	2010-12-30	Anti- hepcidin antibodies and uses thereof
IL200012A0 (en)	2010-04-15	Anti-robo4 antibodies and uses therefor
IL222922A (en)	2015-07-30	Antibodies against neurophilin-1 and their use
IL187710A0 (en)	2008-08-07	Anti-trkb monoclonal antibodies and uses thereof
IL200610A0 (en)	2010-05-17	Human monoclonal anti-ip-10 antibodies and uses thereof
IL192419A0 (en)	2011-08-01	Anti-ephb4 antibodies and methods using same
IL184024A0 (en)	2008-12-29	Irta-5 antibodies and their uses
AP2008004471A0 (en)	2008-06-30	Anti-Alpha2 Intergin antibodies and their uses
SI1964852T1 (sl)	2013-09-30	Proti-ilt7 protitelo
IL231891A (en)	2016-10-31	Anti-ephrinb2 antibodies and methods for their use
EP2077325A4 (en)	2012-04-11	MONOCLONAL ANTIBODY AND ITS USE
ZA201103941B (en)	2012-11-28	Anti-ferroportin 1 monoclonal antibodies and uses thereof
ZA200806053B (en)	2009-12-30	Anti-EphB4 antibodies and methods using same
ZA200905136B (en)	2010-09-29	Anti-robo4 antibodies and uses therefor
HK1145505A (en)	2011-04-21	Anti-chikungunya monoclonal antibodies and uses thereof
ZA200705716B (en)	2008-11-26	IRTA-2 antibodies and their uses